Crude and adjusted odds ratios (OR) and 95% confidence limits (CL) for birth outcome in patients treated with 5-aminosalicylic acid (5-ASA) in pregnancy, using a control group of women treated with 5-ASA before or after pregnancy (control group of women with inflammatory bowel disease)
| Exposed: treated with 5-ASA in pregnancy | Controls: treated with 5-ASA outside pregnancy (ie, more than 3 months before or after pregnancy) | |||
|---|---|---|---|---|
| Events/total (%) | Events/total (%) | OR (crude) (95% CL) | OR (adjusted‡) (95% CL) | |
| *LBW, birth weight less than 2500 g. | ||||
| **Preterm birth, gestational age less than 37 weeks. | ||||
| †Different exposure window when examining congenital malformations (exposed in the period 30 days before conception to the end of first trimester). | ||||
| ‡Adjusted for mother's age (below 25 years, 25–29 years, and 30 years or more), parity (1 or more than 1), smoking (yes/no) in a logistic regression model. LBW and stillbirths also for gestational age (32 weeks or less, 33–36 weeks, and 37 weeks or more). | ||||
| LBW* | 4/88 (4.6) | 9/243 (3.7) | 1.2 (0.4–4.1) | 1.7 (0.5–6.4) |
| Preterm birth** | 8/88 (9.1) | 14/243 (5.8) | 1.6 (0.7–4.0) | 2.0 (0.8–5.0) |
| Stillbirth | 3/88 (3.4) | 2/243 (0.8) | 4.3 (0.7–25.9) | 7.1 (0.2–205.1) |
| Malformation† | 4/60 (6.7) | 10/243 (4.1) | 1.7 (0.5–5.5) | 1.5 (0.4–5.1) |